NASDAQ · GLSI
Greenwich LifeSciences, Inc.
$19.00+$0.69 (+3.77%)
Greenwich LifeSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.28% below the high.
Loading market information…
NASDAQ · PDEX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pro-Dex, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pro-Dex, Inc.’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of $0.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pro-Dex, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 |
|---|
| Sep 3, 2025 |
| $0.36-23.4% vs estimate |
| $17.49M-2.27% vs estimate |
| Q3 2025 | May 1, 2025 | $0.98+108.51% vs estimate | $17.41M-1.62% vs estimate |
|---|
| Q2 2025 | Jan 30, 2025 | $0.61+60.53% vs estimate | $16.79M+21.69% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$19.00+$0.69 (+3.77%)
Greenwich LifeSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.28% below the high.
$2.93-$0.02 (-0.68%)
SkyAI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.71% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$2.06+$0.03 (+1.48%)
Sera Prognostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.49% below the high.
$1.12$0.00 (0.0%)
Microbot Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.84% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
